EW 10-K Analysis: $534M Charge Year Masks a 60% Margin Machine
Edwards Lifesciences reported Q4 GAAP EPS of $0.11 — missing consensus by 82%. But the same filing reveals 60.5% segment operating margins, among the highest in medtech. The $534 million in litigation, impairments, and restructuring charges that crushed reported earnings mask an adjusted operating margin of 29.4%. The real question isn't whether Edwards is profitable — it's whether the TMTT franchise ($551M, +56.4%) can reach contribution-positive scale before TAVR decelerates, while a $920.8 million tax contingency looms over the fortress balance sheet.